STRATA Skin Sciences (SSKN) 10-Q14 May 142014 Q1 Quarterly reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
Document and Entity Information	Mar. 31, 2014	Apr. 30, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Mar-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'
Trading Symbol	'MELA	'
Entity Registrant Name	'MELA SCIENCES, INC. /NY	'
Entity Central Index Key	'0001051514	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	52,107,465

Balance_Sheets

Balance Sheets (USD $)	Mar. 31, 2014	Dec. 31, 2013
Current Assets:	'	'
Cash and cash equivalents	$8,122,709	$3,782,881	[1]
Accounts receivable (net of allowance of $43,080 and $46,130 as of March 31, 2014 and December 31, 2013, respectively)	34,121	57,151	[1]
Inventory (net of reserve of $325,000 as of March 31, 2014 and December 31, 2013)	5,648,020	5,631,205	[1]
Prepaid expenses and other current assets	465,140	879,698	[1]
Total Current Assets	14,269,990	10,350,935	[1]
Property and equipment, net	2,995,253	3,690,784	[1]
Patents and trademarks, net	40,526	41,795	[1]
Other assets	48,000	48,000	[1]
Total Assets	17,353,769	14,131,514	[1]
Current Liabilities:	'	'
Accounts payable (includes related parties of $85,972 and $32,902 as of March 31, 2014 and December 31, 2013, respectively)	1,311,174	1,478,995	[1]
Accrued expenses (includes related parties of $23,129 and $48,000 as of March 31, 2014 and December 31, 2013, respectively)	819,851	844,131	[1]
Deferred placement revenue	201,864	243,605	[1]
Warrant liability	8,464,865	3,017,142	[1]
Other current liabilities	61,815	67,934	[1]
Total Current Liabilities	10,859,569	5,651,807	[1]
Long Term Liabilities:	'	'
Deferred placement revenue	28,834	63,754	[1]
Deferred rent	110,111	120,120	[1]
Total Long Term Liabilities	138,945	183,874	[1]
Total Liabilities	10,998,514	5,835,681	[1]
COMMITMENTS AND CONTINGENCIES	'	'	[1]
Stockholders' Equity:	'	'
Preferred stock - $0.10 par value; authorized 10,000,000 shares: issued and outstanding: 12,300 at March 31, 2014 and 0 at December 31, 2013	1,230	'
Common stock - $0.001 par value; authorized 95,000,000 shares: Issued and outstanding 52,107,465 shares at March 31, 2014 and 47,501,596 at December 31, 2013	52,108	47,502	[1]
Additional paid-in capital	182,430,391	176,396,209	[1]
Accumulated deficit	-176,128,474	-168,147,878	[1]
Total Stockholders' Equity	6,355,255	8,295,833	[1]
Total Liabilities and Stockholders' Equity	$17,353,769	$14,131,514	[1]

[1]	Derived from the audited balance sheet as of December 31, 2013

Balance_Sheets_Parenthetical

Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Statement Of Financial Position [Abstract]	'	'
Allowance for accounts receivable, current	$43,080	$46,130	[1]
Inventory reserves	325,000	325,000	[1]
Accounts payable, related parties	85,972	32,902	[1]
Accrued expenses, related parties	$23,129	$48,000	[1]
Preferred stock, par value	$0.10	$0.10	[1]
Preferred stock, shares authorized	10,000,000	10,000,000	[1]
Preferred stock, shares issued	12,300	0	[1]
Preferred stock, shares outstanding	12,300	0	[1]
Common stock, par value	$0.00	$0.00	[1]
Common stock, shares authorized	95,000,000	95,000,000	[1]
Common stock, shares issued	52,107,465	47,501,596	[1]
Common stock, shares outstanding	52,107,465	47,501,596	[1]

[1]	Derived from the audited balance sheet as of December 31, 2013

Statements_of_Operations

Statements of Operations (USD $)	3 Months Ended
Statements of Operations (USD $)	Mar. 31, 2014	Mar. 31, 2013
Income Statement [Abstract]	'	'
Net revenues	$97,638	$144,100
Cost of revenue	918,523	1,080,263
Gross profit	-820,885	-936,163
Operating expenses:	'	'
Research and development	707,824	1,262,001
Selling, general and administrative	3,203,533	4,287,228
Total operating expenses	3,911,357	5,549,229
Operating loss	-4,732,242	-6,485,392
Other income (expenses):	'	'
Interest income	618	2,105
Interest expense	-1,199	-48,763
Change in fair value of warrant liability	137,142	15,433
Registration rights liquidated damages	-3,389,940	'
Other income, net	5,025	5,000
Non operating income and expense	-3,248,354	-26,225
Net loss	($7,980,596)	($6,511,617)
Basic and diluted net loss per common share	($0.16)	($0.17)
Basic and diluted weighted average number of common shares outstanding	48,926,409	39,233,943

Statements_of_Cash_Flows

Statements of Cash Flows (USD $)	3 Months Ended
Statements of Cash Flows (USD $)	Mar. 31, 2014		Mar. 31, 2013
Cash flows from operating activities:	'		'
Net loss	($7,980,596)		($6,511,617)
Adjustments to reconcile net loss:	'		'
Depreciation and amortization	696,800		496,733
Bad debt expense	700		40,000
Non-cash interest expense	'		14,101
Write-off of unamortized financing costs	'		41,166
Stock-based compensation	164,168		268,381
Change in fair value of warrant liability	-137,142		-15,433
Changes in operating assets and liabilities:	'		'
Accounts receivable	22,330		-29,447
Inventory	-16,815		238,642
Prepaid expenses and other current assets	414,558		89,173
Accounts payable and accrued expenses	-192,101		-834,292
Other current liabilities	-6,119		19,785
Deferred rent	-10,009		-5,913
Deferred revenue	-76,661		88,873
Long-term interest payable	'		7,417
Net cash used in operating activities	-7,120,887		-6,092,431
Cash flows from investing activities:	'		'
Purchases of property and equipment	'		-1,641,297
Net cash used in investing activities	'		-1,641,297
Cash flows from financing activities:	'		'
Net proceeds from private placements/public offerings	11,460,715		15,746,549
Net proceeds from long term debt	'		6,000,000
Expenses related to borrowings and issuance of warrant	'		-245,358
Proceeds from exercise of stock options	'		18,059
Net cash provided by financing activities	11,460,715		21,519,250
Net increase in cash and cash equivalents	4,339,828		13,785,522
Cash and cash equivalents at beginning of period	3,782,881	[1]	7,861,524
Cash and cash equivalents at end of period	8,122,709		21,647,046
Supplemental Schedule of Noncash Investing and Financing Activities:	'		'
Amortization of deferred financing costs	'		$41,166

[1]	Derived from the audited balance sheet as of December 31, 2013

Organization_and_Basis_of_Pres

Organization and Basis of Presentation	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Organization and Basis of Presentation	'
	1. ORGANIZATION AND BASIS OF PRESENTATION
	MELA Sciences, Inc., a Delaware corporation (the “Company”), is a medical device company primarily focused on the commercialization of its flagship product, the MelaFind® system, and the further design and development of MelaFind® and its technology. The MelaFind® system is an optical diagnostic device that assists dermatologists in the diagnosis of melanoma. The MelaFind® system features a hand-held component that uses light of differing wavelengths to capture digital data from clinically atypical pigmented skin lesions. The data are then analyzed utilizing sophisticated classification algorithms that have been ‘trained’ and blind tested on the Company’s proprietary database of melanomas and benign lesions. The MelaFind® system then provides images and objective data on the relative disorganization of a lesion’s structure that provides substantial additional perspective to assist physicians in the clinical management decision for atypical pigmented skin lesions, including information useful in the decision whether to biopsy the lesion.
	The components of the MelaFind® system include:

		•	a hand-held component, which employs high precision optics and multi-spectral illumination (multiple colors of light including near infra-red);

		•	a proprietary database of pigmented skin lesions, believed to be the largest positive prospective database to date in the US; and

		•	lesion classifiers, which are sophisticated mathematical algorithms that extract lesion feature information and classify lesions.
	In November 2011, the Company received written approval from the U.S. Food and Drug Administration (“FDA”) for the MelaFind® Pre-Market Approval (“PMA”) application and in September 2011 received Conformite Europeenne (“CE”) Mark approval. In March 2012, the Company installed the first commercial MelaFind® systems, and proceeded with the commercial launch of MelaFind®. The Company is currently conducting a Post-Approval Study (“PAS”) evaluating the sensitivity and false positive rate of physicians after using the MelaFind® system to their performance if MelaFind® was not available.
	In 2012 the Company evolved from a research and development company to a commercial enterprise. The launch of MelaFind® in 2012 and the subsequent commercialization activities supporting the launch did not meet the Company’s initial goals and objectives. Revenues were lower than forecasted and expenses continued to increase throughout 2012 and into 2013.
	In the third quarter of 2013, a significant cost reduction program was put into place. In November 2013, the Company appointed a new CEO and adopted a refocused “Go-to-Market” strategy concentrating on key institutions, opinion leaders and dermatologists who treat many of the patients at high risk for melanoma. As part of this strategy, in late December 2013, the Company changed its business model for the MelaFind® system from a rental-based to a sales-based model. The Company has reduced its costs, added more experience to its management team, and reorganized its sales and marketing activities to better support the commercialization of the MelaFind® system. The Company is also seeking a coverage determination from the Centers for Medicare & Medicaid Services, the federal agency that administers Medicare, as a prerequisite to obtain reimbursement by Medicare for use of the MelaFind® system. This process could take up to two years. Once a coverage determination has been made, the Company plans to seek reimbursement by Medicaid, Medicare and other third-party payers.
	On August 22, 2013, the Company received a notice from The NASDAQ Stock Market that, for the previous 30 consecutive business days, the Company was not in compliance with the minimum bid price requirement of $1.00 per share for continued listing on the NASDAQ Capital Market. The Company was granted an automatic 180 grace period by NASDAQ in which to regain compliance. On February 19, 2014, the Company was notified by NASDAQ that the Company was eligible for an additional 180 day grace period and has until August 18, 2014 to regain compliance with NASDAQ’s minimum bid price requirement or risk delisting.
	On October 17, 2013, the FDA notified the Company that its report with respect to the PAS was inadequate to allow the agency to complete its review, and as a result revised the PAS status on the FDA website to “Progress Inadequate.” In January 2014, the Company’s revised enrollment plan and schedule was approved by the FDA and the interactive review process was closed. On April 2, 2014, the FDA updated the study status to “Progress Adequate” and approved our new study timeline. The Company currently targets submission of the PAS report the FDA by year-end 2017.
	In February 2014, the Company sold to two investors (the “Purchasers”) (i) an aggregate of 12,300 shares of Series A Convertible Preferred Stock, (the “Series A Preferred Stock”), convertible into 14,642,857 shares of common stock at an initial conversion price of $0.84, and (ii) warrants to purchase up to 13,297,297 shares of the Company’s common stock, for net proceeds of approximately $11.4 million. The warrants have an exercise price of $0.74 per share, are immediately exercisable and have a term of five years. The number of shares issuable upon conversion of the Series A Preferred Stock and exercise of the warrants are adjustable in the event of stock splits, stock dividends, combinations of shares and similar transactions. The Purchasers have been granted rights of participation in future offerings of our securities for one year. In addition, as a condition of the financing, the Company’s directors purchased an aggregate of 202,703 shares of common stock at a price of $0.74 per share, for aggregate gross proceeds of $150,000.
	The warrant obligation fell within the scope of Accounting Standards Codification 815 “Derivatives and Hedging” (“ASC 815”) and therefore the warrant obligation was accounted for as a derivative.
	In connection with this financing, the Company also granted to the Purchasers resale registration rights with respect to the shares of common stock underlying the Series A Preferred Stock and the warrants pursuant to the terms of a Registration Rights Agreement. The Purchasers were entitled to receive liquidated damages upon the occurrence of a number of events relating to filing, effectiveness and maintaining an effective registration statement covering the shares underlying the Series A Preferred Stock and the warrants. The Company was unable to meet certain filing and effectiveness requirements and as a result paid liquidated damages to the Purchasers in the aggregate amount of approximately $3.4 million. Under the terms of the Registration Rights Agreement, the Company filed a registration statement on March 18, 2014, which was declared effective by the SEC on April 3, 2014. Should this registration statement cease to remain effective for more than ten consecutive calendar days or more than an aggregate of 15 calendar days during any 12-month period, the Company would be subject to additional liquidated damages of up to approximately $500,000.
	The unaudited condensed financial statements included herein have been prepared from the books and records of the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for reporting on Form 10-Q. The information and note disclosures normally included in complete financial statements prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) have been condensed or omitted pursuant to such rules and regulations. The interim financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013.
	The Company’s management is responsible for the financial statements included in this document. The Company’s interim financial statements are unaudited. Interim results may not be indicative of the results that may be expected for the year. However, the Company believes all adjustments considered necessary for a fair presentation of these interim financial statements have been included and are of a normal and recurring nature.
	Liquidity
	The Company has experienced recurring losses and negative cash flow from operations and management expects these conditions to continue for the foreseeable future. As a result of these factors, the Company has been and continues to be dependent on raising capital from the sale of securities in order to continue to operate and to meet its obligations in the ordinary course of business. In February 2014, as noted above, the Company raised net proceeds of approximately $11.5 million from the sale of Series A Preferred Stock, common stock and warrants to strengthen the Company’s financial position.
	The Company’s net losses have had a significant negative impact on working capital and its financial position and may impact the Company’s future ability to meet its obligations in the ordinary course of business. As a result, management believes that there is significant doubt about the Company’s ability to continue as a going concern. The Company continues to assess the effects of its previously announced cost reduction plan and is prepared to reduce various operational costs as necessary. Although the Company has no specific arrangements or plans, additional capital will be needed during the upcoming months, which may take the form of equity, equity-linked or debt financing. In addition, the Company anticipates that long-term it will need to raise funds to support further advances in the technology and clinical trials. The timing and amount of any additional funding the Company may require will be affected by numerous factors, many of which are not in the control of the Company including the market acceptance of the MelaFind® system.
	There can be no assurances that the Company will be able to raise additional financing in the future. Additional funds may not become available on acceptable terms or at all and there can be no assurance that any additional funding the Company obtains will be sufficient to meet the Company’s financing needs. Any additional funding that the Company may obtain in the future could be dilutive to common stockholders, provide new investors with rights and preferences senior to common stockholders and provide for restrictive covenants that could limit the Company’s ability to take certain actions. Unless the Company is able to generate sufficient revenues or to raise additional capital near-term, the Company’s operations will be scaled back to maintain only vital activities, or discontinued.

Use_of_Estimates

Use of Estimates	3 Months Ended
Use of Estimates	Mar. 31, 2014
Text Block [Abstract]	'
Use of Estimates	'
	2. USE OF ESTIMATES
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires the use of estimates and assumptions by management that affect reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to stock-based compensation arrangements, the use of estimates to determine the elements of our revenue and deferred revenue, accrued expenses, and the warrant liability. Actual results could differ from these estimates. Estimates of future operating results are based upon numerous factors including past experience, known information and subjective estimates and assumptions. Actual future operating results could be materially different from management’s estimates and unforeseen events could adversely affect management’s estimates.

Recent_Accounting_Pronouncemen

Recent Accounting Pronouncements	3 Months Ended
Recent Accounting Pronouncements	Mar. 31, 2014
Accounting Changes And Error Corrections [Abstract]	'
Recent Accounting Pronouncements	'
	3. RECENT ACCOUNTING PRONOUNCEMENTS
	The Financial Accounting Standards Board has issued a number of new accounting standards that require future adoption. Based on the Company’s initial review of these new standards, none are expected to have a material impact on the Company’s financial statements.

Inventories

Inventories	3 Months Ended
Inventories	Mar. 31, 2014
Inventory Disclosure [Abstract]	'
Inventories	'
	4. INVENTORIES
	Inventories currently consist of MelaFind® systems and other finished products and accessories that are stated at the lower of cost or market value. Inventory accessories are purchased items to be sold for use in the operation of the MelaFind® systems. The Company maintains a reserve for specific inventory items that are no longer being used in the devices.
	In December 2013, the Company changed its business model for the MelaFind® system from a rental-based model to a sales-based model. In accordance with this new sales model, the Company reclassified approximately $5.4 million of MelaFind® systems from property and equipment into inventory at December 31, 2013.
	Inventory consists of the following:


		March 31,			December 31,
		2014			2013
	MelaFind® Systems	$	5,401,866		$	5,401,866
	Mela record cards		324,685			327,900
	Accessories		246,469			226,439

			5,973,020			5,956,205
	Reserve for obsolete inventory		(325,000	)		(325,000	)

		$	5,648,020		$	5,631,205

Fixed_Assets

Fixed Assets	3 Months Ended
Fixed Assets	Mar. 31, 2014
Property Plant And Equipment [Abstract]	'
Fixed Assets	'
	5. FIXED ASSETS
	The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An asset is considered to be impaired when the sum of the undiscounted future net cash flows expected to result from the use of the asset and its eventual disposition exceeds its carrying amount. The amount of impairment loss, if any, is measured as the difference between the net book value of the asset and its estimated fair value.
	In December 2013, the Company changed its business model for the MelaFind® system from a rental-based to a sales-based model. In accordance with this new sales model, the Company reclassified approximately $5.4 million of MelaFind® systems from property and equipment into inventory at December 31, 2013. The systems reclassified into inventory represent new and unused systems. Systems that have been leased under the rental-based model remain in property and equipment.
	Property and equipment, at cost, consists of the following:


		March 31,			December 31,			Estimated
		2014			2013			Useful Life	Useful Life

	Leasehold improvements	$	905,888		$	905,888		Lease Term	Lease Term
	Laboratory and research equipment		1,083,661			1,083,661		3-5 years	3-5 years
	Office furniture and equipment		2,022,833			2,022,833		3-5 years	3-5 years
	MelaFind® Systems		5,081,816			5,081,816		3 years	3 years

			9,094,198			9,094,198
	Accumulated depreciation and amortization		(6,098,945	)		(5,403,414	)

		$	2,995,253		$	3,690,784

Net_Loss_Per_Common_Share

Net Loss Per Common Share	3 Months Ended
Net Loss Per Common Share	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Net Loss Per Common Share	'
	6. NET LOSS PER COMMON SHARE
	Basic net loss per common share excludes dilution for potentially dilutive securities and is computed by dividing loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share gives effect to dilutive options, warrants and other potential common shares outstanding during the period. Diluted net loss per common share is equal to the basic net loss per common share since all potentially dilutive securities are anti-dilutive for each of the periods presented. Potential common stock equivalents outstanding as of March 31, 2014 and March 31, 2013 consist of common stock equivalents of convertible preferred stock, stock options, common stock purchase warrants and restricted stock, which are summarized as follows:


		March 31,
		2014		2013

	Common stock equivalents of convertible preferred stock		14,642,857		—
	Common stock options		2,907,574		1,435,314
	Common stock purchase warrants		21,047,641		200,000
	Restricted stock awards		65,050		—

	Total		38,663,122		1,635,314

Comprehensive_Loss

Comprehensive Loss	3 Months Ended
Comprehensive Loss	Mar. 31, 2014
Equity [Abstract]	'
Comprehensive Loss	'
	7. COMPREHENSIVE LOSS
	For all periods presented, the Company had no comprehensive income items and accordingly there is no difference between the reported net loss and per share amounts per the Statement of Operations and comprehensive net loss and related per share amounts.

StockBased_Compensation

Stock-Based Compensation	3 Months Ended
Stock-Based Compensation	Mar. 31, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Stock-Based Compensation	'
	8. STOCK-BASED COMPENSATION
	Stock awards under the Company’s stock option plans have been granted with exercise prices that are no less than the market value of the stock on the date of the grant. Options granted under the 2013 and 2005 Plans are generally time-based or performance-based options and vesting varies accordingly. Options under the plans expire up to a maximum of ten years from the date of grant.
	The fair value of each option award granted is estimated on the date of grant using the Black-Sholes option valuation model and assumptions as noted in the following table:


		March 31,
		2014	2013

	Expected life	6.5 years	6.5 years
	Expected volatility	75.51%	76.83%
	Risk-free interest rate	2.14-2.45%	1.25-1.38%
	Dividend yield	—	—

Debt

Debt	3 Months Ended
Debt	Mar. 31, 2014
Debt Disclosure [Abstract]	'
Debt	'
	9. DEBT
	On March 15, 2013, the Company executed loan documents with Hercules Technology Growth Capital Inc., a venture capital lender, whereby the Company borrowed $6 million (the “Loan”). The Loan accrued interest at a rate of 10.45%. The term of the Loan was 42 months with interest payments only during the first 12 months. On September 10, 2013, the Company elected to prepay the Loan and paid Hercules approximately $6.4 million, including the end of term fee of $425,000, to settle all obligations to Hercules. Hercules agreed to waive the prepayment penalty of $180,000.
	Upon executing the loan documents on March 15, 2013 the Company became obligated to issue to the Lender a warrant to purchase shares of the Company’s common stock upon approval by the Company’s stockholders of a proposal to increase the Company’s number of authorized shares of common stock at its 2013 Annual Meeting of Stockholders. The number of shares that could be acquired upon exercise of the warrant and the exercise price per share were not fixed on March 15, 2013, but would be determined when the warrant was issued based on a defined formula using trading prices of the Company’s common stock during certain periods prior to the issuance of the warrant. The Company’s stockholders approved the increase in the number of authorized shares of common stock on April 25, 2013 and on April 26, 2013 the warrant was issued to the Lender. The terms of the warrant were fixed on the date of issuance whereby the Lender received a warrant to purchase 693,202 shares of common stock at an exercise price of approximately $1.12 per share. The warrant expires on April 26, 2018.

	For financial reporting purposes, the $6 million funded by the Lender on March 15, 2013 was allocated first to the fair value of the obligation to issue the warrant, which totaled approximately $563,000, and the balance was reduced further by the Lender’s costs and fees, resulting in an initial carrying value of the loan of approximately $5.3 million. The Company used a Level 3 fair value measurement to determine fair value of the warrant obligation, which has significant unobservable inputs as defined in Accounting Standards Codification 820 “Fair Value Measures”. During the period from the loan inception date until the warrant obligation was fulfilled and the warrant was issued, the warrant obligation was reflected as a long-term liability at fair value. Changes in the fair value (“mark-to-market adjustments”) of the warrant obligation of approximately $15,000 are included in operating results for the three months ended March 31, 2013. The fair value of the warrant obligation was determined using the Monte Carlo pricing model that used various assumptions that included: stock prices ranging from $1.16 to $1.18 per share, volatility of 77%, time to maturity of 5 years, exercise prices ranging from $1.15 to $1.16 and a risk free interest rate of return of .84%. Under the Monte Carlo model, a 10% change in the underlying unobservable inputs would not have a significant impact on the fair value.
	The value of the warrant obligation combined with the costs resulted in an initial loan discount of approximately $727,000. The terms of the Loan required us to pay the Lender a fee of $425,000 at the maturity of the Loan. The loan discount and the fee were being amortized as additional interest expense over the life of the loan using the interest method. As discussed above, prior to the terms of the warrant being fixed on April 26, 2013, the warrant obligation fell within the scope of Accounting Standards Codification 815 “Derivatives and Hedging” (“ASC 815”) and therefore the warrant obligation was accounted for as a derivative reflected as a long-term liability until the warrant was issued on April 26, 2013. The terms of the warrant upon issuance no longer required derivative accounting under ASC 815 and therefore the fair value of the warrant was classified within stockholders equity.
	As the result of the Company electing to prepay the loan on September 10, 2013, the unamortized loan discount, fee and deferred financing costs that were expensed at that date were approximately $1.0 million.

Stockholders_Equity

Stockholders' Equity

3 Months Ended

Mar. 31, 2014

Equity [Abstract]

Stockholders' Equity

10. STOCKHOLDERS’ EQUITY

Preferred Stock

The Company is authorized to issue 10,000,000 shares of preferred stock with a par value of $0.10 per share with such designation, rights and preferences as may be determined from time to time by the Company’s Board of Directors.

As discussed in detail in Note 1, on February 5, 2014, pursuant to a securities purchase agreement, dated as of January 31, 2014, the Company sold to the Purchasers (i) an aggregate of 12,300 shares of Series A Convertible Preferred Stock, par value $0.10 and a stated value of $1,000 per share, convertible into 14,642,857 shares of common stock at an initial conversion price of $0.84, and (ii) warrants to purchase up to 13,297,297 shares of common stock for net proceeds of $11.4 million. The warrants have an exercise price of $0.74 per share, are immediately exercisable and have a term of five years. These warrants have non-standard terms as they relate to a fundamental transaction and require a net-cash settlement upon a change in control of the Company and therefore are classified as a derivative liability and recorded at fair value on the inception date of February 5, 2014, and will be recorded at their respective fair value at each subsequent balance sheet date. The fair value of these warrants on March 31, 2014 was equivalent to the fair value on February 5, 2014, and therefore no change in fair value has been recorded for the three months ended March 31, 2014.

In connection with this financing, the Company also granted to the Purchasers resale registration rights with respect to the shares of common stock underlying the Series A Preferred Stock and the warrants pursuant to the terms of a Registration Rights Agreement. The Purchasers were entitled to receive liquidated damages upon the occurrence of a number of events relating to filing, effectiveness and maintaining an effective registration statement covering the shares underlying the Series A Preferred Stock and the warrants. The Company was unable to meet certain filing and effectiveness requirements and as a result paid liquidated damages to the Purchasers in the aggregate amount of approximately $3.4 million. Under the terms of the Registration Rights Agreement, the Company filed a registration statement on March 18, 2014, which was declared effective by the SEC on April 3, 2014. Should this registration statement cease to remain effective for more than ten consecutive calendar days or more than an aggregate of 15 calendar days during any 12-month period, the Company would be subject to additional liquidated damages of up to approximately $500,000.

Common Stock

The Company is authorized to issue 95,000,000 shares of common stock with a par value of $0.001 per share.

On October 29, 2013, the Company entered into a securities purchase agreement with certain accredited investors in connection with a $6.0 million registered offering of 4,228,181 shares of the Company’s common stock, fully paid prefunded warrants (“Series B Warrants”) to purchase up to 4,343,247 shares of its common stock and additional warrants (“Series A Warrants”) to purchase up to 6,857,142 shares of its common stock. The Series A Warrants are exercisable beginning on May 1, 2014 at a price of $0.85 per share and expire on May 1, 2019. The Series B Warrants are exercisable immediately for no additional consideration. The offering closed on October 31, 2013.

The holders exercised 2,000,000 and 2,343,247 on March 5, 2014 and March 7, 2014, respectively, of the Series B Warrants. There were no warrant exercises in the first quarter of 2013.

The Series A Warrants have non-standard terms as they relate to a fundamental transaction and require a net-cash settlement upon a change in control of the Company and therefore are classified as a derivative. Therefore, these warrants have been recorded at fair value at the inception date of October 31, 2013, and will be recorded at their respective fair values at each subsequent balance sheet date. Any change in value between reporting periods will be recorded as a non-operating, non-cash charge in the Statements of Operations. The change in fair value of the warrant liability for the three months ended March 31, 2014, was $137,000.

On February 12, 2013 the Company entered into an underwriting agreement with Cowen and Company, LLC, relating to the public offering of 6.1 million shares of the Company’s common stock, at a price to the public of $1.30 per share less underwriting discounts and commissions. The gross proceeds to the Company from the sale of the Common Stock totaled $7.9 million. After deducting the underwriters’ discounts and commissions and other estimated offering expenses payable by the Company, net proceeds were approximately $7.3 million. The offering closed on February 15, 2013.

In June 2012, the Company entered into a sales agreement with Cowen and Company, LLC, to sell shares of the Company’s common stock through an “at-the-market” equity offering program (the “ATM Program”), which was terminated on February 15, 2013. During the three months ended March 31, 2013, and in connection with its termination, the Company sold approximately 4.7 million shares under the ATM Program for gross and net proceeds of approximately $8.8 million and $8.5 million, respectively. During the term of the ATM Program, the Company sold a total of approximately 6.6 million shares for aggregate gross and net proceeds of approximately $14.4 million and $13.8 million, respectively.

Outstanding common stock warrants consist of the following:

Issue Date

Expiration Date

Total

Ex. Price

Warrants

5/7/09

5/7/14

200,000

11.35

4/26/13

4/26/18

693,202

1.12

10/31/13

10/31/18

6,857,142

0.85

2/5/14

2/5/19

13,297,297

0.74

21,047,641

During the three months ended March 31, 2014, the number of outstanding shares of the Company’s common stock increased from 47,501,596 to 52,107,465.

Fair_Value_of_Financial_Instru

Fair Value of Financial Instruments	3 Months Ended
Fair Value of Financial Instruments	Mar. 31, 2014
Fair Value Disclosures [Abstract]	'
Fair Value of Financial Instruments	'
	11. FAIR VALUE OF FINANCIAL INSTRUMENTS
	Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value for applicable assets and liabilities, we consider the principal or most advantageous market in which we would transact and we consider assumptions market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. This guidance also establishes a fair value hierarchy to prioritize inputs used in measuring fair value as follows:

		•		Level 1: Observable inputs such as quoted prices in active markets;

		•		Level 2: Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and

		•		Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.
	The Company’s financial instruments are cash and cash equivalents, accounts payable, and derivative warrant liabilities. The recorded values of cash equivalents and accounts payable approximate their fair values based on their short-term nature. The fair value of derivative warrant liabilities is estimated using option pricing models that are based on the individual characteristics of our warrants, preferred and common stock, the derivative warrant liability on the valuation date as well as assumptions for volatility, remaining expected life, risk-free interest rate and, in some cases, credit spread. The derivative warrant liabilities are the only recurring Level 3 fair value measures.

	A summary of quantitative information with respect to the valuation methodology and significant unobservable inputs used for the Company’s warrant liabilities that are categorized within Level 3 of the fair value hierarchy as of March 31, 2014 and December 31, 2013 is as follows:


			March 31, 2014		December 31, 2013

	Stock Price		$0.62		$	0.64
	Risk-free Rate (5-year U.S. Treasury Yield)		1.73%			1.75	%
	Volatility (Annual)		93.46%			93.43	%
	Time to Maturity (Years)		4.85-5.08			5.33
	Derivative warrant liabilities consist of the following:


			Fair Value
			Measurements Using
			Significant
			Unobservable Inputs
			(Level 3)
			Warrant Derivative
			Liabilities
	Beginning balance at January 1, 2014		$	3,017,142
	Issuance of warrants with derivative liabilities			5,584,865
	Changes in estimated fair value			(137,142	)

	Ending balance at March 31, 2014		$	8,464,865

Inventories_Tables

Inventories (Tables)	3 Months Ended
Inventories (Tables)	Mar. 31, 2014
Inventory Disclosure [Abstract]	'
Schedule of Inventory	'
	Inventory consists of the following:


		March 31,			December 31,
		2014			2013
	MelaFind® Systems	$	5,401,866		$	5,401,866
	Mela record cards		324,685			327,900
	Accessories		246,469			226,439

			5,973,020			5,956,205
	Reserve for obsolete inventory		(325,000	)		(325,000	)

		$	5,648,020		$	5,631,205

Fixed_Assets_Tables

Fixed Assets (Tables)	3 Months Ended
Fixed Assets (Tables)	Mar. 31, 2014
Property Plant And Equipment [Abstract]	'
Summary of Property and Equipment	'
	Property and equipment, at cost, consists of the following:


		March 31,			December 31,			Estimated
		2014			2013			Useful Life	Useful Life

	Leasehold improvements	$	905,888		$	905,888		Lease Term	Lease Term
	Laboratory and research equipment		1,083,661			1,083,661		3-5 years	3-5 years
	Office furniture and equipment		2,022,833			2,022,833		3-5 years	3-5 years
	MelaFind® Systems		5,081,816			5,081,816		3 years	3 years

			9,094,198			9,094,198
	Accumulated depreciation and amortization		(6,098,945	)		(5,403,414	)

		$	2,995,253		$	3,690,784

Net_Loss_Per_Common_Share_Tabl

Net Loss Per Common Share (Tables)	3 Months Ended
Net Loss Per Common Share (Tables)	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Schedule of Common Stock Equivalents of Convertible Preferred Stock, Stock Options, Common Stock Purchase Warrants and Restricted Stock	'
	Potential common stock equivalents outstanding as of March 31, 2014 and March 31, 2013 consist of common stock equivalents of convertible preferred stock, stock options, common stock purchase warrants and restricted stock, which are summarized as follows:


		March 31,
		2014		2013

	Common stock equivalents of convertible preferred stock		14,642,857		—
	Common stock options		2,907,574		1,435,314
	Common stock purchase warrants		21,047,641		200,000
	Restricted stock awards		65,050		—

	Total		38,663,122		1,635,314

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	3 Months Ended
Stock-Based Compensation (Tables)	Mar. 31, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Schedule of Fair Value of Each Option Award Granted	'
	The fair value of each option award granted is estimated on the date of grant using the Black-Sholes option valuation model and assumptions as noted in the following table:


		March 31,
		2014	2013

	Expected life	6.5 years	6.5 years
	Expected volatility	75.51%	76.83%
	Risk-free interest rate	2.14-2.45%	1.25-1.38%
	Dividend yield	—	—

Stockholders_Equity_Tables

Stockholders' Equity (Tables)

3 Months Ended

Mar. 31, 2014

Equity [Abstract]

Schedule of Outstanding Common Stock Warrants

Outstanding common stock warrants consist of the following:

Issue Date

Expiration Date

Total

Ex. Price

Warrants

5/7/09

5/7/14

200,000

11.35

4/26/13

4/26/18

693,202

1.12

10/31/13

10/31/18

6,857,142

0.85

2/5/14

2/5/19

13,297,297

0.74

21,047,641

Fair_Value_of_Financial_Instru1

Fair Value of Financial Instruments (Tables)	3 Months Ended
Fair Value of Financial Instruments (Tables)	Mar. 31, 2014
Fair Value Disclosures [Abstract]	'
Schedule of Fair Value Hierarchy	'
	A summary of quantitative information with respect to the valuation methodology and significant unobservable inputs used for the Company’s warrant liabilities that are categorized within Level 3 of the fair value hierarchy as of March 31, 2014 and December 31, 2013 is as follows:


		March 31, 2014		December 31, 2013

	Stock Price	$0.62		$	0.64
	Risk-free Rate (5-year U.S. Treasury Yield)	1.73%			1.75	%
	Volatility (Annual)	93.46%			93.43	%
	Time to Maturity (Years)	4.85-5.08			5.33
Schedule of Derivative Warrant Liabilities	'
	Derivative warrant liabilities consist of the following:


		Fair Value
		Measurements Using
		Significant
		Unobservable Inputs
		(Level 3)
		Warrant Derivative
		Liabilities
	Beginning balance at January 1, 2014	$	3,017,142
	Issuance of warrants with derivative liabilities		5,584,865
	Changes in estimated fair value		(137,142	)

	Ending balance at March 31, 2014	$	8,464,865

Organization_and_Basis_of_Pres1

Organization and Basis of Presentation - Additional Information (Detail) (USD $)	0 Months Ended		1 Months Ended	3 Months Ended			0 Months Ended		1 Months Ended
	Feb. 19, 2014	Aug. 22, 2013	Feb. 28, 2014	Mar. 31, 2014	Dec. 31, 2013		Apr. 03, 2014	Feb. 05, 2014	Feb. 28, 2014
							Subsequent Event [Member]	Common Stock Equivalents of Convertible Preferred Stock [Member]	Common Stock Equivalents of Convertible Preferred Stock [Member]
									Investor
Condensed Financial Statements, Captions [Line Items]	'	'	'	'	'		'	'	'
Number of consecutive business days, non-compliance of minimum bid price	'	'30 days	'	'	'		'	'	'
Minimum bid price	'	$1	'	'	'		'	'	'
Grace period granted by NASDAQ to regain compliance	'	'180 days	'	'	'		'	'	'
Additional grace period	'180 days	'	'	'	'		'	'	'
Number of purchasers of preferred stock and warrants	'	'	'	'	'		'	'	2
Preferred stock, shares issued	'	'	'	12,300	0	[1]	'	12,300	12,300
Preferred stock converted to common stock, shares	'	'	'	'	'		'	14,642,857	14,642,857
Preferred stock converted to common stock, conversion price	'	'	'	'	'		'	$0.84	$0.84
Warrants issued to purchase common stock	'	'	'	'	'		'	13,297,297	13,297,297
Proceeds from issuance of warrants	'	'	'	'	'		'	$11,400,000	$11,400,000
Warrants issued, exercise price	'	'	'	'	'		'	0.74	0.74
Warrants issued, exercisable term	'	'	'	'	'		'	'5 years	'5 years
Purchasers granted rights	'	'	'1 year	'	'		'	'	'
Common stock purchased, shares	'	'	202,703	'	'		'	'	'
Common stock purchased, share price	'	'	$0.74	'	'		'	'	'
Proceeds from common stock purchased	'	'	150,000	'	'		'	'	'
Liquidated damages paid	'	'	'	-3,389,940	'		'	'	'
Registration rights agreement description	'	'	'	'Under the terms of the Registration Rights Agreement, the Company filed a registration statement on March 18, 2014, which was declared effective by the SEC on April 3, 2014. Should this registration statement cease to remain effective for more than ten consecutive calendar days or more than an aggregate of 15 calendar days during any 12-month period, the Company would be subject to additional liquidated damages of up to approximately $500,000	'		'	'	'
Additional liquidated damages payable	'	'	'	'	'		$500,000	'	'

[1]	Derived from the audited balance sheet as of December 31, 2013

Inventories_Additional_Informa

Inventories - Additional Information (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Inventory [Line Items]	'	'
Inventory, Gross	$5,973,020	$5,956,205
MelaFind Systems [Member]	'	'
Inventory [Line Items]	'	'
Inventory, Gross	$5,401,866	$5,401,866

Inventories_Schedule_of_Invent

Inventories - Schedule of Inventory (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Inventory [Line Items]	'	'
Inventory, Gross	$5,973,020	$5,956,205
Reserve for obsolete inventory	-325,000	-325,000	[1]
Inventory, Net	5,648,020	5,631,205	[1]
MelaFind Systems [Member]	'	'
Inventory [Line Items]	'	'
Inventory, Gross	5,401,866	5,401,866
Mela Record Cards [Member]	'	'
Inventory [Line Items]	'	'
Inventory, Gross	324,685	327,900
Accessories [Member]	'	'
Inventory [Line Items]	'	'
Inventory, Gross	$246,469	$226,439

[1]	Derived from the audited balance sheet as of December 31, 2013

Fixed_Assets_Additional_Inform

Fixed Assets - Additional Information (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]	'	'
Inventory, Gross	$5,973,020	$5,956,205
MelaFind Systems [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Inventory, Gross	$5,401,866	$5,401,866

Fixed_Assets_Summary_of_Proper

Fixed Assets - Summary of Property and Equipment (Detail) (USD $)	3 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]	'	'
Gross	$9,094,198	$9,094,198
Accumulated depreciation and amortization	-6,098,945	-5,403,414
Net	2,995,253	3,690,784	[1]
Leasehold Improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Gross	905,888	905,888
Estimated Useful Life	'Lease Term	'
Useful Life	'Lease Term	'
Laboratory and Research Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Gross	1,083,661	1,083,661
Estimated Useful Life	'3-5 years	'
Office Furniture and Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Gross	2,022,833	2,022,833
Estimated Useful Life	'3-5 years	'
MelaFind Systems [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Gross	$5,081,816	$5,081,816
Estimated Useful Life	'3 years	'
Useful Life	'3 years	'
Minimum [Member] \| Laboratory and Research Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Useful Life	'3 years	'
Minimum [Member] \| Office Furniture and Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Useful Life	'3 years	'
Maximum [Member] \| Laboratory and Research Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Useful Life	'5 years	'
Maximum [Member] \| Office Furniture and Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Useful Life	'5 years	'

[1]	Derived from the audited balance sheet as of December 31, 2013

Net_Loss_Per_Common_Share_Sche

Net Loss Per Common Share - Schedule of Common Stock Equivalents of Convertible Preferred Stock, Stock Options, Common Stock Purchase Warrants and Restricted Stock (Detail)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Potential common stock equivalents	38,663,122	1,635,314
Common Stock Options [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Potential common stock equivalents	2,907,574	1,435,314
Warrants Derivative Liabilities [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Potential common stock equivalents	21,047,641	200,000
Restricted Stock Awards [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Potential common stock equivalents	65,050	'
Common Stock Equivalents of Convertible Preferred Stock [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Potential common stock equivalents	14,642,857	'

Comprehensive_Loss_Additional_

Comprehensive Loss - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Net Income Loss [Abstract]	'	'
Comprehensive income (loss)	$0	$0

StockBased_Compensation_Additi

Stock-Based Compensation - Additional Information (Detail)	3 Months Ended
Stock-Based Compensation - Additional Information (Detail)	Mar. 31, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Expiry period of option plan	'10 years

StockBased_Compensation_Schedu

Stock-Based Compensation - Schedule of Fair Value of Each Option Award Granted (Detail)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'	'
Expected life	'6 years 6 months	'6 years 6 months
Expected volatility	75.51%	76.83%
Risk-free interest rate - Minimum	2.14%	1.25%
Risk-free interest rate - Maximum	2.45%	1.38%
Dividend yield	'	'

Debt_Additional_Information_De

Debt - Additional Information (Detail) (USD $)

0 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

0 Months Ended

3 Months Ended

Sep. 10, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 15, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 15, 2013

Mar. 31, 2014

Sep. 10, 2013

Warrant Obligation [Member]

Minimum [Member]

Maximum [Member]

Hercules Technology Growth Capital Inc. [Member]

Warrant Obligation [Member]

Debt Instrument [Line Items]

Loan payable

$6,000,000

Accrued interest rate

10.45%

Maturity period of loan

'42 months

Time period of interest payment

'First 12 months

Prepayment of loan

6,400,000

Term fee

425,000

Prepayment penalty

180,000

Warrants issued to purchase common stock

693,202

Warrants issued to purchase common stock, exercise price

1.12

Expiry date for warrant outstanding

26-Apr-18

Warrant issuance date

25-Apr-13

Fair value of warrant obligation

563,000

Initial carrying value of the loan

5,300,000

Changes in fair value of warrants

137,000

15,000

Stock prices

$1.16

$1.18

Volatility

93.46%

93.43%

77.00%

Maturity period

'5 years 3 months 29 days

'5 years

'4 years 10 months 6 days

'5 years 29 days

Exercise prices

$0.62

$0.64

$1.15

$1.16

Risk free interest rate of return

1.73%

1.75%

0.84%

Change in underlying unobservable inputs

10.00%

Initial loan discount amount

727,000

Loss on early extinguishment of debt

$1,000,000

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)

3 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

3 Months Ended

0 Months Ended

3 Months Ended

Mar. 31, 2014

Dec. 31, 2013

Oct. 29, 2013

Feb. 05, 2014

Feb. 28, 2014

Mar. 31, 2014

Feb. 12, 2013

Apr. 03, 2014

Mar. 07, 2014

Mar. 05, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Oct. 29, 2013

Mar. 31, 2014

Common Stock Equivalents of Convertible Preferred Stock [Member]

Securities Purchase Agreement [Member]

Shelf Registration Statement [Member]

Subsequent Event [Member]

Series B Prefunded Warrants [Member]

Minimum [Member]

Maximum [Member]

Series B Prefunded Warrants [Member]

Series A Warrants [Member]

ATM Program [Member]

Securities Financing Transaction [Line Items]

Preferred stock, shares authorized

10,000,000

[1]

Preferred stock, par value

$0.10

[1]

Preferred stock, shares issued

12,300

[1]

12,300

Preferred stock, par value

$0.10

Preferred stock stated value, per share

$1,000

Preferred stock converted to common stock, shares

14,642,857

Preferred stock converted to common stock, conversion price

$0.84

Warrants issued to purchase common stock

13,297,297

Proceeds from issuance of warrants

$11,400,000

Warrants issued to purchase common stock, exercise price

0.74

0.85

Warrants issued, exercisable term

'5 years

Derivative fair value inception date

5-Feb-14

Liquidated damages paid

-3,389,940

Registration rights agreement description

'Under the terms of the Registration Rights Agreement, the Company filed a registration statement on March 18, 2014, which was declared effective by the SEC on April 3, 2014. Should this registration statement cease to remain effective for more than ten consecutive calendar days or more than an aggregate of 15 calendar days during any 12-month period, the Company would be subject to additional liquidated damages of up to approximately $500,000

Additional liquidated damages payable

500,000

Common stock, shares authorized

95,000,000

[1]

Common stock, par value

$0.00

[1]

Common stock issued

52,107,465

47,501,596

[1]

4,228,181

Warrants issued to purchase common stock

4,343,247

6,857,142

Proceeds from issuance of common stock and warrants

6,000,000

Warrants exercisable date

1-May-14

Warrants expiry date

1-May-19

Offering closed date

31-Oct-13

Warrants exercised

2,343,247

2,000,000

Change in fair value of warrant liability

137,000

Public offering of common stock shares under underwriting agreement

6,100,000

Initial public offering price per share

$1.30

Gross proceeds from sale of common stock

7,900,000

Net proceeds from sale of common stock

7,300,000

Sales agreement termination date

15-Feb-13

Number of common stock issued through company ATM program

4,700,000

6,600,000

Gross proceeds from sale of common stock

8,800,000

14,400,000

Net proceeds from sale of common stock

$8,500,000

$13,800,000

Number of outstanding common stock shares increased

47,501,596

52,107,465

[1]

Derived from the audited balance sheet as of December 31, 2013

Stockholders_Equity_Schedule_o

Stockholders' Equity - Schedule of Outstanding Common Stock Warrants (Detail)	Mar. 31, 2014
Class of Warrant or Right [Line Items]	'
Total Warrants	21,047,641
Ex. Price $ 11.35 [Member]	'
Class of Warrant or Right [Line Items]	'
Issue Date	7-May-09
Expiration Date	7-May-14
Total Warrants	200,000
Ex. Price	11.35
Ex. Price $ 1.12 [Member]	'
Class of Warrant or Right [Line Items]	'
Issue Date	26-Apr-13
Expiration Date	26-Apr-18
Total Warrants	693,202
Ex. Price	1.12
Ex. Price $ 0.85 [Member]	'
Class of Warrant or Right [Line Items]	'
Issue Date	31-Oct-13
Expiration Date	31-Oct-18
Total Warrants	6,857,142
Ex. Price	0.85
Ex. Price $ 0.74 [Member]	'
Class of Warrant or Right [Line Items]	'
Issue Date	5-Feb-14
Expiration Date	5-Feb-19
Total Warrants	13,297,297
Ex. Price	0.74

Fair_Value_of_Financial_Instru2

Fair Value of Financial Instruments - Schedule of Fair Value Hierarchy (Detail) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'
Stock Price	$0.62	$0.64
Risk-free Rate	1.73%	1.75%
Volatility (Annual)	93.46%	93.43%
Time to maturity (Years)	'	'5 years 3 months 29 days
Minimum [Member]	'	'
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'
Time to maturity (Years)	'4 years 10 months 6 days	'
Maximum [Member]	'	'
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'
Time to maturity (Years)	'5 years 29 days	'

Fair_Value_of_Financial_Instru3

Fair Value of Financial Instruments - Schedule of Derivative Warrant Liabilities (Detail) (Significant Unobservable Inputs (Level 3) [Member], Warrants Derivative Liabilities [Member], USD $)	3 Months Ended
	Mar. 31, 2014
Significant Unobservable Inputs (Level 3) [Member] \| Warrants Derivative Liabilities [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Beginning balance at January 1, 2014	$3,017,142
Issuance of warrants with derivative liabilities	5,584,865
Changes in estimated fair value	-137,142
Ending balance at March 31, 2014	$8,464,865